Leading ladies: The women heading the biggest family-led hotels in Asia
The daughter of Malaysia's richest man, Robert Kuok , Hui Kwong was appointed chief executive of the prestigious hotel group on Aug 1. She is the sixth of his eight children and has been Shangri-La's executive director and chairwoman since 2016 and 2017, respectively.
BT highlights some of the women who have risen to the apex of command at hotel chains across Asia.
Wee Wei Ling - Pan Pacific Hotels Group
Wei Ling is the daughter of late banker Wee Cho Yaw and sister of UOB CEO Wee Ee Cheong PHOTO: Pan Pacific Hotels Group
The executive director (Asset, Lifestyle & Community Partnerships) of Pan Pacific Hotels Group, Wee Wei Ling, has been in the hospitality business for 36 years. Wee, 73, oversees the asset management of the group's hotel properties to managing its sustainability strategy.
A scion of UOB's Wee family and daughter of the late billionaire banker Wee Cho Yaw , she co-founded Extra.Ordinary People, a charity that helps special needs individuals gain skills to improve their employability.
A NEWSLETTER FOR YOU
Tuesday, 12 pm Property Insights
Get an exclusive analysis of real estate and property news in Singapore and beyond.
Sign Up
Sign Up
Wee, a Nanyang University political science graduate, was entrusted to run the Si Chuan Dou Hua Restaurant, a lifestyle brand under the hotel group, in 1996. The restaurant now has outlets in Singapore, Japan and Myanmar, while the Pan Pacific group has three brands – Pan Pacific, Parkroyal Collection, and Parkroyal – straddling over 30 cities in Asia Pacific, Africa, North America and Europe.
Nikki Ng - Sino Group
Ng is the eldest daughter of property tycoon Robert Ng from the Far East family. PHOTO: Nikki Ng
Nikki Ng hails from a long line of legendary property magnates in the Far East family. She is the eldest daughter of Singaporean businessman Robert Ng, who is the son of the late real estate billionaire Ng Teng Fong. Her uncle is Far East Organization CEO Philip Ng.
Ng has been part of the Hong Kong-headquartered Sino Group since 2002, and currently serves as its non-executive director and director of philanthropy.
The group comprises Sino Land Company, Tsim Sha Tsui Properties and Sino Hotels (Holdings). Its core business is property development for sales and investment, though it is also a major player in hotel investment and management.
Yale-educated Ng has driven charitable initiatives at Sino, like the non-profit Hong Kong Innovation Foundation and its integrated green community project Farm Together. She previously also served as the group's general manager from 2002 until 2023, before moving onto her current role.
Dawn Teo - Amara Hotels and Resorts
Teo's grandfather Teo Joo Lai developed the Amara hotel. PHOTO: Amara Holdings
The senior vice-president of Amara Hotels and Resorts and the director of Strategic Planning and Corporate Development for Amara Holdings, Dawn Teo is also part of a well-known family business.
Her great-grandfather, Teo Teck Huat, founded the company in the 1930s as the Teo Teck Huat Group. It was initially involved in construction, including development of the iconic Cathay Cinema at Handy Road in the 1930s, before expanding its core business areas and changing its name.
The Amara Singapore hotel was developed and built by Dawn Teo's grandfather, Teo Joo Lai, and opened in 1986. Dawn graduated from the Wharton School at the University of Pennsylvania and worked in investment banking and wealth management for 15 years before joining the family business.
Outside of the family business, Teo is also the co-founder and director of Objectifs – Centre for Photography and Film, a non-profit visual arts centre that supports filmmakers and photographers.
Kuok Hui Kwong - Shangri-La Asia
Hui Kwong is the daughter of business tycoon and centenarian Robert Kuok. She was also the former chief executive of the South China Morning Post. PHOTO: Shangri-La Asia
The new CEO of Shangri-La Asia, Kuok Hui Kwong was promoted to the corner office on Aug 1.
She is the daughter of business tycoon and centenarian Robert Kuok, the founder of Shangri-La and the richest man in Malaysia. The chairwoman of the group since 2017 and its executive director since 2016, she was also the former chief executive of the South China Morning Post.
Harvard-educated Kuok was ranked the 40th most powerful woman in Asia in a Fortune magazine list last year. Her brother Kuok Khoon Hua, also a Harvard alumni, is a director the Kuok Group, and chairman of Kerry Holdings.
The Shangri-La Group, founded in 1971, operates over 100 hotels under its four brands; Shangri-La, Kerry, Hotel Jen and Traders. It owned 81 of those properties as at the end of the 2024 financial year.
Sonia Cheng - Rosewood Group
Cheng is a scion of the family behind New World Development and Chow Tai Fook Jewellery. PHOTO: Rosewood Hotels & Resorts
Trained in applied mathematics at Harvard, Rosewood CEO Sonia Cheng is at the helm of a group with three hotels in the World's 50 Best Hotels list, with Rosewood Hong Kong in third place.
Like the other women heading hotel groups on this list, Cheng is from a storied and wealthy family. Her grandfather was Hong Kong billionaire Cheng Yu-tung, who escaped the war in mainland China in 1938 to found the real estate and investment conglomerate New World Development. He later also took over the Chow Tai Fook Jewellery store from his father-in-law.
Her father, Henry Cheng, is now the chairman of New World Development and the Chow Tai Fook Jewellery store, with Sonia Cheng the vice-president of the latter.
Cheng started her career in banking and finance before joining the family business as CEO at the age of 28, driving the expansion of Rosewood. This includes the first hotel to open under her leadership, the Rosewood London in 2013. She has since added the wellness concept Asaya, kids' club programme Rosewood Explorers Club and private members' club Carlyle & Co to the group's portfolio.
Lee Boo-Jin - Hotel Shilla
Lee is the younger sister of Samsung Electronics executive chairman Lee Jae-yong. PHOTO: Yonhap News/Newscom
The president and CEO of South Korea's Hotel Shilla, Lee Boo-Jin, is the younger sister of Samsung Electronics executive chairman Lee Jae-yong and elder sister of Samsung Welfare Foundation chairman Lee Seo-hyun.
Their father is Samsung Group patriarch Lee Kun-hee, with Boo-Jin previously having been the chairman of Samsung Construction and Trading Corporation.
Hotel Shilla operates 19 luxury hotels in South Korea and one in Vietnam, with Lee Boo-jin at the helm since 2011. It also owns duty-free stores at Seoul's Incheon and Singapore's Changi airports.
Lee is also considered a style icon in South Korea and had her name changed from Lee Yoo-jin at the age of three. She studied locally at Yonsei University, unlike her siblings, and was ranked the ninth-richest person in Korea in 2025 by Forbes.
Ho Ren Yung - Banyan Group
Ho is deputy CEO of luxury resort group Banyan Group. PHOTO: Banyan Group
The deputy CEO of the Banyan Group, Ho Ren Yung has been part of her family's business since 2009.
The daughter of the group's co-founders Ho Kwon Ping and Claire Chiang, Ho Ren Yung studied at the London School of Economics and oversaw the company's brand relaunch with 18 hotel openings in 2024. She took on the deputy CEO role a year ago.
Her parents established the luxury resort group in 1994, which now has 10 global brands. It manages and develops resorts, hotels and spas across the world in Asia, Europe, North America and Africa. Most recently, it opened the Mandai Rainforest Resort in the Mandai Wildlife Reserve.
Ho has also co-founded co-working space Kennel and was also the founding member of AVPN Asia Gender Network and Creative Mornings in Singapore.
Naphaporn Bodiratnangkura - Nai Lert Group
Bodiratnangkura is a fourth generation leader of the hospitality company. PHOTO: Aman Nai Lert Bangkok
The CEO of Nai Lert Group and Nai Lert Park Development, Naphaporn Bodiratnangkura is a fourth generation leader of the hospitality company.
The eponymous Nai Lert was named after her great-grandfather, who started the firm in 1894 as an imported goods business. It later expanded into hotels and transport and is now involved in real estate, education and culture beyond its core hospitality focus.
At 11, the Bangkok-born Bodiratnangkura was sent to an all-girls boarding school in the United Kingdom. She went on to study hotel management at the University of Surrey before moving to New York to study at the Parsons School of Design.
When called back to Thailand by her grandmother, she thought her return would be short-lived. Having made her way up to the top job, Bodiratnangkura is now plugging gaps within Thailand's hospitality sector through her family business.
Charintip Tiyaphorn - Pimalai Resort & Spa
Tiyaphorn is the owner representative at Pimalai Resort & Spahe resort. PHOTO: Pimalai Resort & Spa
The owner representative of Pimalai Resort & Spa in Thailand, Charintip Tiyaphorn also started her career away from the family business. She initially worked in auditing, before completing a master's in marketing and management.
After her graduation, she was coaxed to her father's hotel to lead the accounting and finance department, before also taking over the sales and marketing department. Today, she is the owner representative at the resort.
Located on Koh Lanta, Pimalai Resort was opened in 2001 by Tiyaphorn's father, Anurat Tiyaphorn, a former lawyer. Today, it boasts a reputation of being one of the most luxurious resorts on the island. It is also one of only 78 hotels to feature on the Small Luxury Hotels of the World's (SLH) Considerate Collection for its sustainability efforts.
Carolyn Choo - Worldwide Hotels Group
Choo was a bank management trainee when she was called upon to join her father at Worldwide Hotels Group. PHOTO: Carolyn Choo
The CEO and managing director of Worldwide Hotels Group, Carolyn Choo received an urgent call from billionaire hotelier Choo Chong Ngen , her father, in 2002 to join the family business.
At the time, she had been a management trainee at a local bank for over three years. Today, she has been in the top job for eight years.
Worldwide Hotels Group manages brands, including the well-known Hotel 81 chain. It also owns the Novotel Singapore on Kitchener hotel and the Mercure Icon hotel in Singapore, alongside 11 other hotels in the Asia-Pacific region.
The group has grown significantly since Choo joined, from having just three degree holders and 12 Hotel 81 properties to a key player in affordable hospitality today.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
3 hours ago
- Business Times
New acquisition, healthcare segment fuelling Sunningdale Tech: non-exec chairman Koh Boon Hwee
[SINGAPORE] Precision plastics engineering company Sunningdale Tech has continued to grow even after delisting from the Singapore Exchange (SGX) in 2021, and has now acquired an industry peer. The company purchased Sanwa Group for an undisclosed sum on Aug 7, with the deal expected to grow Sunningdale's revenue to S$850 million. Sunningdale's non-executive chairman Koh Boon Hwee liked this acquisition in particular as it allows a Singaporean company to remain in the hands of a Singapore business. 'I actually prefer that outcome rather than having it being sold to a non-Singaporean entity. I'm hopeful that the combination will allow both companies to continue to grow together,' Koh told The Business Times. The acquisition makes sense for Sunningdale as Sanwa's main business segment is industrial, adding on to the former's precision consumer, automotive and healthcare segments. While Sanwa has an automotive segment in its revenue stream, the products are different from Sunningdale's. This means there is no overlap of product offerings, giving Sunningdale an expanded product range in the automotive segment. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up 'On top of that, it brings us from 17 plants to 23 plants, and I think that's very helpful for our combined customer base,' said Koh. These plants are spread out over nine markets and most continents, which gives flexibility to Sunningdale's customers, he added. With the world unlikely to return any time soon to a global trade system that allowed goods and people to move more easily across borders, it was fortunate that Sunningdale acquired its first US plant back in 2020. The footprint of that facility has trebled since the purchase, standing it in good stead as customers there decide if they should onshore some of their production. 'The fragmentation (means that) the trading system we have been used to for the last 30 years isn't going to come back; so I have to adapt Sunningdale to this new reality,' said Koh. The acquisition of Sanwa was financed by internal resources and a 'small bank loan', he added, without Sunningdale having to turn to fundraising from external parties. Integrating the company with Sunningdale is not expected to take too long, as the intention is to retain most of its employees. Besides this acquisition, Sunningdale is also growing its healthcare segment, which has seen double-digit growth annually for the last six years, from 10 per cent of revenue in 2018 to about 30 per cent currently. The goal now is to expand the segment to more than 40 per cent in the next four years. The consumer and automotive segments will also enlarge in tandem, but due to their mature nature and reliance on macroeconomic conditions, they cannot grow as fast as healthcare, noted Koh. Sunningdale has also continued to grow organically since delisting. Growth and exits Based on filings pulled by data platform Handshakes, Sunningdale's 2024 revenue stood at S$722.7 million. The company breached S$700 million in 2021, and revenue has been above this mark since then. Earnings too have hovered around S$35 million for 2023 and 2024, with net profit margins hovering between 4 and 5.7 per cent between 2020 and 2024. The variance in earnings is due to Sunningdale's customers' product road maps, where old products may be wound down more quickly than new products are ramped up, said Koh. 'But because we are highly diversified, our business actually hasn't been that cyclical. Our growth is steady,' he noted, adding that there has not been much volatility in Sunningdale's revenue. Its team has been disciplined on costs, and ensures that no one customer accounts for more than 10 per cent of its revenue. This growth has continued despite foreign exchange headwinds, which have resulted in Sunningdale taking a 5 to 6 per cent hit in revenue. This is the main challenge the company faces – but it is on track to still expand about 1 to 2 per cent this year. Koh does not rule out a return to the SGX as part of providing a liquidity event for Sunningdale's investors, which includes its employees. But currently, plans are still open-ended, as the company has no shortage of private investors. 'There are advantages to being a private company. We are in no hurry,' said Koh. Sunningdale also would not turn down investments from parties such as 65 Equity Partners if they are open to it. But Koh noted that while SGX is an option, especially amid moves to make the local bourse more attractive, any pressure to return might not work. 'The conditions have to be correct, you can't pressure companies to do things they don't want to do.'
Straits Times
7 hours ago
- Straits Times
Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
Sign up now: Get ST's newsletters delivered to your inbox Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. SINGAPORE – Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium -sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Mr Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Dr Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion (S$132.4 billion) in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Dr Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targeted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Dr Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Dr Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Dr Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Dr Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. Correction note: In an earlier version of the story, we referred to the company's chief scientific officer and co-founder as Mr Boyd-Kirkup. This is incorrect. His correct form of address is Dr Boyd-Kirkup.
Business Times
15 hours ago
- Business Times
United Overseas Insurance aims to increase technology investments by almost 50% by 2029
[SINGAPORE] United Overseas Insurance (UOI), the general insurance arm of UOB, will increase its technology investments by almost 50 per cent from 2023 levels by 2029. This will involve rolling out digital initiatives designed to enhance customer journeys and upgrading the insurer's core technology infrastructure, it said on Wednesday (Aug 13). 'These enhanced capabilities will enable the company to scale operations, improve service delivery, and respond more effectively to evolving customer expectations.' A digital intermediary portal launching in August will enable intermediaries to reach a broader customer base, especially those underserved by traditional channels. Motor and travel insurance now have fully digitalised product journeys, offering customers greater convenience and accessibility. UOI plans to extend this digital experience across all products by 2026. UOI will also streamline customer engagement and service feedback through messaging apps such as WhatsApp. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up On Wednesday, the group further said that it plans to increase talent acquisition by more than 60 per cent by 2029 in Singapore and across the region. This will support the insurer's accelerated growth and help it implement succession planning. UOI also said it is expanding its insurance products to meet the needs of its customers. For instance, it partnered UOB to launch InsureCruise, Singapore's first dedicated cruise insurance to address specific risks such as missed port departures, itinerary changes due to weather, and on-board medical emergencies. 'Unlike standard travel insurance plans, this plan helps customers avoid paying for benefits that are unnecessary for a cruise trip, such as rental vehicle excess or flight misconnection coverage,' UOI said.
